This explains why other i.v. iron formulations do not cause hypophosphatemia, and why intact (active) FGF23 increases more than c-terminal FGF23 in ferric carboxymaltose-induced hypophosphatemia (30, 51, 52). Here, FGF23 is linked to hypophosphatemia.